Cytokinetics (CYTK) to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with HCM
Go back to Cytokinetics (CYTK) to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with HCM| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 78.78 +0.67 (0.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $78.11 | 52 Week High | $13.18 | |||
| Open | $79.41 | 52 Week Low | $6.00 | |||
| Day High | $80.15 | P/E | N/A | |||
| Day Low | $77.14 | EPS | $-1.24 | |||
| Volume | 3,547,472 | |||||
